| 1 |
32735740 | Pharmacological evaluation of imidazole-derived bisphosphonates on receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and function. | 2021 Jan |
1 |
| 2 |
33837656 | Upregulation of mmu_circ_0001066 attenuates the inhibitory effect of bisphosphonates on osteoclastogenesis. | 2021 Apr 9 |
1 |
| 3 |
30909508 | Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. | 2019 Mar 22 |
2 |
| 4 |
31260659 | Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons. | 2019 Oct |
1 |
| 5 |
26874195 | Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling. | 2016 Mar 1 |
1 |
| 6 |
25532478 | Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid. | 2015 Apr |
1 |
| 7 |
26085098 | Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. | 2015 Jul 31 |
2 |
| 8 |
24490900 | Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. | 2014 Feb 3 |
1 |
| 9 |
22447156 | Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. | 2012 Jun |
1 |
| 10 |
22579611 | Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. | 2012 Sep 25 |
3 |
| 11 |
19405951 | RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. | 2009 |
3 |